On 11 November, the European Medicines Agency (EMA) authorised VidPrevtyn Beta, a COVID-19 vaccine booster dose, for use in people ages 18 and older who received an mRNA or adenoviral vaccine for the primary series. The EMA also updated its clinical data for the Spikevax COVID-19 vaccine. The data supports the use of Spikevax in chidlren aged 6 months to five years old.